The city’s top homelessness official quietly created a new housing strategy over the past year to operate outside agreed-upon protocols between Metro and other service providers. The program preceded ...

Embark on a fulfilling pharmacy career with our Pharmacy Technician Training Program. Our 16-week program allows you to gain the skills required for safe patient care. The self-paced format ensures ...

Schneider Electric's SCADAPack 474i remote terminal unit (RTU). Nozomi Networks, a cybersecurity supplier for OT (operational technology), IoT (Internet of Things) and CPS (cyber physical systems), ...

Nozomi Networks Inc. and Schneider Electric have introduced the first security sensor embedded directly into Schneider Electric remote terminal units (RTUs). The integration of Nozomi Arc Embedded ...

LINDALE, Texas (KLTV) - A fire in Lindale has destroyed a house and car and a child is being treated for smoke inhalation. The fire started after 11 a.m. in the 12900 block of County Road 474.

In a sweeping move to combat systemic fraud, the Minnesota Department of Human Services (DHS) has formally requested to terminate its Housing Stabilization Services (HSS) program. The $100-million-per ...

SALISBURY, MD- A first-of-its-kind alcohol program is coming to downtown Salisbury. The city is launching what's called To-go Alcohol in Public Spaces, or T.A.P.S. Officials say it will allow for ...

Gov. Kathy Hochul announced Wednesday the expansion of New York state’s Veterans Tuition Awards program. Under this expansion, all veterans who served at least four years on active-duty now qualify ...

Kymera Therapeutics has announced that Sanofi will advance their next-generation oral IRAK4 degrader, KT-485, into clinical testing, while opting not to pursue KT-474. Preclinical studies indicated ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 ...

Kymera Therapeutics said Sanofi has pulled the plug on the most advanced drug candidate in the companies' partnership aimed at immune-inflammatory diseases but plans to advance a second candidate into ...